Singapore markets close in 33 minutes
Straits Times Index
3,380.84 +17.16 (+0.51%) Nikkei
27,509.46 +107.41 (+0.39%) Hang Seng
21,660.47 -297.89 (-1.36%) FTSE 100
7,818.09 -2.07 (-0.03%) BTC-USD
23,399.60 -431.24 (-1.81%) CMC Crypto 200
533.89 -11.42 (-2.10%)
UroGen Pharma Ltd. (0XOD.L)
LSE - LSE Delayed Price. Currency in USD
Add to watchlist
As of 06:31PM GMT. Market open.
| Previous close | 8.00 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 1.134M |
| Beta (5Y monthly) | 0.69 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.05 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer
PRINCETON, N.J., January 11, 2023--JELMYTO Real-World Data Published in Journal of Urologic Oncology
- Business Wire
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
PRINCETON, N.J., December 19, 2022--UroGen Completes Enrollment of its Phase 3 study for UGN-102 in development for treatment of LG-IR-NMIBC
- Business Wire
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PRINCETON, N.J., December 09, 2022--UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 12 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercial launch of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the c
© 2023 Yahoo. All rights reserved.
